{
    "clinical_study": {
        "@rank": "107570", 
        "acronym": "OZDRY", 
        "arm_group": [
            {
                "arm_group_label": "Ozurdex PRN dosing", 
                "arm_group_type": "Active Comparator", 
                "description": "Ozurdex PRN dosing versus Ozurdex fixed dosing"
            }, 
            {
                "arm_group_label": "Ozurdex fixed dosing", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 \u00b5g\n      Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical\n      coherence tomography (OCT)-guided PRN dosing in patients with refractory diabetic macular\n      edema."
        }, 
        "brief_title": "Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 \u03bcg Dexamethasone", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects of either sex aged 18 years or over\n\n          2. Diagnosis of diabetes mellitus (type 1 or type 2).\n\n          3. Best corrected visual acuity in the study eye between \u226534 and \u226473 ETDRS letters at 1m\n             at baseline attributable to diabetic macular edema (DME)\n\n          4. On clinical exam at baseline in the study eye, retinal thickening due to diabetic\n             macular oedema involving the centre of the macula and OCT central subfield > 300\n             microns despite previous therapy.\n\n          5. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate\n             fundus photographs.\n\n          6. Ability to return for study visits\n\n          7. Visual acuity in fellow eye \u2265 2/60\n\n          8. Ability to give informed consent throughout the duration of the study\n\n        Main Exclusion Criteria:\n\n          1. Macular ischaemia\n\n          2. Macular oedema is considered to be due to a cause other than diabetic macular oedema.\n\n          3. Co-existent ocular disease\n\n          4. An ocular condition is present (other than diabetes) that, in the opinion of the\n             investigator,  might affect macular oedema or alter visual acuity during the course\n             of the study.\n\n          5. A substantial cataract that, in the opinion of the investigator, is likely to be\n             decreasing visual acuity by 3 lines or more."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892163", 
            "org_study_id": "SIVS1007"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ozurdex PRN dosing", 
                "Ozurdex fixed dosing"
            ], 
            "description": "Dexamethasone implant (Ozurdex)", 
            "intervention_name": "Ozurdex", 
            "intervention_type": "Device", 
            "other_name": "Dexamethasone"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Diabetic macular edema, Ozurdex", 
        "lastchanged_date": "July 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "EC1V 2PD"
                }, 
                "name": "Moorfields Eye Hospital NHS Foundation trust"
            }, 
            "investigator": {
                "last_name": "Sobha Sivaprasad, FRCS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 \u03bcg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema", 
        "overall_contact": {
            "email": "sobha.sivaprasad@moorfields.nhs.uk", 
            "last_name": "Sobha Sivaprasad, FRCS", 
            "phone": "07817886759"
        }, 
        "overall_contact_backup": {
            "email": "vicky.mccudden@moorfields.nhs.uk", 
            "last_name": "Vicky McCudden", 
            "phone": "02075662019"
        }, 
        "overall_official": {
            "affiliation": "Moorfields Eye Hospital NHS Foundation Trust", 
            "last_name": "Sobha Sivaprasad, FRCS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Health Service", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The difference between arms in the change from baseline in best corrected visual acuity at 12 months", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892163"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Moorfields Eye Hospital NHS Foundation Trust", 
            "investigator_full_name": "Sobha Sivaprasad", 
            "investigator_title": "Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Difference between arms in change from baseline in each domain and composite scores of the National Eye Institute Visual function questionnaire (VFQ-25).", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Difference between arms in change in central subfield thickness.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Proportion of patients with ocular and systemic serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Moorfields Eye Hospital NHS Foundation Trust", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Royal Wolverhampton Hospital NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Frimley Park Hospital NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Brighton and Sussex University Hospitals NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospitals Bristol NHS Foundation Trust", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Moorfields Eye Hospital NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}